Summary of Key Information:

Reporting Period: Quarter and Financial Year ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 and 33 of SEBI Listing Regulations

Audit Opinion:

Unmodified opinion from S.R. Batliboi & Associates LLP on both standalone and consolidated financial results for the financial year ended March 31, 2026.

Key Financial Highlights [Rs. in Million]:

Standalone Results:

Quarter ended March 31, 2026:

  • Revenue from Operations: 4,080.64
  • Total Income: 4,133.04
  • Net Profit: 593.05
  • EPS: ₹5.85 (Basic and Diluted)

Year ended March 31, 2026:

  • Revenue from Operations: 15,456.60
  • Total Income: 15,891.14
  • Net Profit: 2,500.16
  • EPS: ₹24.62 (Basic and Diluted)
  • Other Equity: 15,874.98
  • Cash and Cash Equivale nts: 172.80

Consolidated Results:

Quarter ended March 31, 2026:

  • Revenue from Operations: 4,599.01
  • Total Income: 4,649.65
  • Net Profit: 782.18
  • Attributable to owners: 770.43
  • Non-controlling interests: 11.75
  • EPS: ₹7.59 (Basic and Diluted)

Year ended March 31, 2026:

  • Revenue from Operations: 17,030.77
  • Total Income: 17,468.65
  • Net Profit: 2,815.44
  • Attributable to owners: 2,783.23
  • Non-controlling interests: 32.21
  • EPS: ₹27.41 (Basic and Diluted)
  • Other Equity: 15,465.15
  • Cash and Cash Equivalents: 338.94

Exceptional Items:

An exceptional item of ₹15.39 million was recognized in both standalone and consolidated results due to the implementation of New Labour Codes, resulting in an increase in provision for defined benefit obligation.

Corporate Actions:

  • Recommended final dividend of ₹3.5 per equity share (35%) on face value of ₹10 per share for FY26
  • Dividend aggregating to ₹355.46 million
  • Subject to shareholder approval at 28th AGM on July 29, 2026
  • Record date fixed as Tuesday, July 21, 2026
  • Dividend to be dispatched/credited within 30 days from AGM conclusion

Director Reappointments:

1. Dr. Ramesh Kancharla (DIN: 00212270) reappointed as Chairman and Managing Director for 5 years from August 11, 2026 to August 10, 2031

2. Dr. Dinesh Kumar Chirla (DIN: 01395841) reappointed as Whole Time Director for 5 years from August 11, 2026 to August 10, 2031

3. Mr. Santanu Mukherjee reappointed as Independent Director for second term of 5 years from October 22, 2026 to October 21, 2031

4. Ms. Sundari R. Pisupati reappointed as Independent Director for second term of 5 years from September 16, 2026 to September 15, 2031

Other Appointments:

  • Reappointment of M/s. Lavanya & Associates LLP as Cost Auditors for FY 2026-27

ESOP Grants:

  • Granted 267,550 stock options under ESOP 2025 to eligible employees
  • Exercisable into 267,550 equity shares of face value ₹10 each
  • Exercise price to be determined at discount of not more than 20% on latest available closing price as on May 22, 2026
  • Minimum vesting period: 1 year, maximum period: 10 years
  • Exercise period: maximum 2 years from each vesting date

Acquisition Details:

1. Acquired 76% equity and 100% preference shares of Prashanthi Medicare Private Limited for ₹326.00 million (effective July 1, 2025)

  • Recognized net assets: ₹121.11 million, goodwill: ₹204.44 million
  • Contributed revenue: ₹191.52 million, PBT: ₹8.54 million

2. Acquired 76% equity and 100% preference shares of Pratiksha Women & Child Care Hospital Private Limited for ₹1,710 million (effective August 18, 2025)

  • Recognized net assets: ₹349.46 million, goodwill: ₹1,364.46 million
  • Contributed revenue: ₹648.70 million, PBT: ₹136.73 million

Annual General Meeting:

  • 28th AGM to be held on Wednesday, July 29, 2026 through Video Conferencing/Other Audio-Visual Means